| 0.122 -0.014 (-10.29%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.31  |
1-year : | 0.41 |
| Resists | First : | 0.26 |
Second : | 0.35 |
| Pivot price | 0.15 |
|||
| Supports | First : | 0.12 |
Second : | 0.1 |
| MAs | MA(5) : | 0.13 |
MA(20) : | 0.16 |
| MA(100) : | 0.32 |
MA(250) : | 2.19 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 1.8 |
D(3) : | 2.2 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 33.65 | Low : | 0.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LIMN ] has closed above bottom band by 8.6%. Bollinger Bands are 81.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 70 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.14 - 0.14 | 0.14 - 0.14 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.12 - 0.12 | 0.12 - 0.12 |
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Wed, 03 Jun 2026
[8-K] Liminatus Pharma, Inc. Reports Material Event - Stock Titan
Fri, 22 May 2026
Liminatus Pharma (LIMN) Stock: Nasdaq Delisting Warning Sparks Volatile Trading Session - Blockonomi
Fri, 22 May 2026
Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance with Market Value Requirements - Quiver Quantitative
Wed, 25 Feb 2026
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Live Price, Chart & News - CoinCodex
Tue, 17 Feb 2026
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 38.5 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 562 (K) |
| Shares Short P.Month | 1,990 (K) |
| EPS | -0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.49 |
| PEG Ratio | 0 |
| Price to Book value | -0.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|